Topical Rapamycin to Treat Fibrofolliculomas in Birt-Hogg-Dubé Syndrome
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Significant regression of lesions (reduction of fibrofolliculoma size and count) in the treated area.
3 and 6 months
Maurice van Steensel, Dr.
Department of Dermatology
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)